PEGylation of supercooled smectic cholesteryl myristate nanoparticles

Supercooled smectic cholesterol ester nanoparticles are under investigation as a new carrier system for lipophilic drugs. The smectic thermotropic liquid crystalline state of the matrix lipid is expected to lead to advantages with respect to physicochemical stability and drug loading capacity. Such nanoparticles can be prepared by high-pressure melt homogenization in the presence of emulsifiers. The purpose of this study was to develop PEGylated supercooled smectic cholesteryl myristate nanoparticles for parenteral administration and to provide evidence of the successful PEGylation by detecting the alterations of particle properties due to the insertion of PEGylated phospholipid into the surface layer of the particles. To achieve PEGylation, MPEG(2000)-DSPE was processed together with the phospholipids used as emulsifiers during particle preparation. The influence of the PEGylated phospholipid on the size, zeta potential, phase behavior and recrystallization tendency of the nanoparticles indicated the insertion of MPEG(2000)-DSPE into the surface layer of the particles. Evidence of the PEGylation was also obtained by (1)H NMR measurements, and the steric stabilization was verified by neutralizing the particle surface charge with calcium chloride or adjusting the pH value. As sterility is an important aspect with regard to parenteral administration of the dispersions their stability upon autoclaving was a further point of interest in the present study. The results indicate that PEGylated particles can be sterilized by autoclaving. In conclusion, the PEGylated particles are a promising formulation with respect to small particle size, stability against recrystallization and upon autoclaving.